BR112015002483A2 - composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis - Google Patents

composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis

Info

Publication number
BR112015002483A2
BR112015002483A2 BR112015002483A BR112015002483A BR112015002483A2 BR 112015002483 A2 BR112015002483 A2 BR 112015002483A2 BR 112015002483 A BR112015002483 A BR 112015002483A BR 112015002483 A BR112015002483 A BR 112015002483A BR 112015002483 A2 BR112015002483 A2 BR 112015002483A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
treating
mycobacterium tuberculosis
active infection
Prior art date
Application number
BR112015002483A
Other languages
English (en)
Portuguese (pt)
Inventor
N Coler Rhea
G Reed Steven
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of BR112015002483A2 publication Critical patent/BR112015002483A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015002483A 2012-08-03 2013-08-02 composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis BR112015002483A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679612P 2012-08-03 2012-08-03
US201361791213P 2013-03-15 2013-03-15
PCT/US2013/053482 WO2014042780A1 (en) 2012-08-03 2013-08-02 Compositions and methods for treating an active mycobacterium tuberculosis infection

Publications (1)

Publication Number Publication Date
BR112015002483A2 true BR112015002483A2 (pt) 2017-11-07

Family

ID=50278593

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002483A BR112015002483A2 (pt) 2012-08-03 2013-08-02 composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis

Country Status (13)

Country Link
US (2) US20150182612A1 (cg-RX-API-DMAC7.html)
EP (2) EP4299138A3 (cg-RX-API-DMAC7.html)
JP (1) JP2015525784A (cg-RX-API-DMAC7.html)
CN (1) CN104812404A (cg-RX-API-DMAC7.html)
BR (1) BR112015002483A2 (cg-RX-API-DMAC7.html)
ES (1) ES2969734T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240164T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065746T2 (cg-RX-API-DMAC7.html)
MX (1) MX385774B (cg-RX-API-DMAC7.html)
PT (1) PT2879701T (cg-RX-API-DMAC7.html)
RU (1) RU2659149C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014042780A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201501242B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458088A2 (en) * 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
RU2262950C2 (ru) * 2001-03-23 2005-10-27 Каунсил Оф Сайентифик Энд Индастриал Рисерч Способ получения вакцины для лечения туберкулеза и других внутриклеточных инфекционных заболеваний и вакцина, полученная по названному способу
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
EP1991213A2 (en) * 2006-02-08 2008-11-19 Fasgen, Inc. Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008124647A2 (en) * 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
WO2010010178A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
EP2353008A2 (en) * 2008-09-22 2011-08-10 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
CA2808556A1 (en) * 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis

Also Published As

Publication number Publication date
HRP20240164T1 (hr) 2024-04-12
MX2015001557A (es) 2015-10-08
EP2879701B1 (en) 2023-11-15
CN104812404A (zh) 2015-07-29
JP2015525784A (ja) 2015-09-07
EP2879701A1 (en) 2015-06-10
US11369672B2 (en) 2022-06-28
EP2879701A4 (en) 2016-01-20
ES2969734T3 (es) 2024-05-22
US20200038498A1 (en) 2020-02-06
ZA201702091B (en) 2018-12-19
MX385774B (es) 2025-03-18
US20150182612A1 (en) 2015-07-02
PT2879701T (pt) 2024-02-12
ZA201501242B (en) 2017-08-30
EP4299138A3 (en) 2024-08-14
RU2659149C2 (ru) 2018-06-28
EP4299138A2 (en) 2024-01-03
RU2015107435A (ru) 2016-09-27
HUE065746T2 (hu) 2024-06-28
WO2014042780A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
BR112015011830A2 (pt) compostos e seus métodos de utilização
BR112015028152A2 (pt) inibidores de acc e usos dos mesmos
AR087956A1 (es) METODOS Y COMPOSICIONES QUE MODULAN ACETIL-CoA CARBOXILASA PARA EL CONTROL DE MALEZAS
MX2015001557A (es) Composiciones y metodos para tratar una infeccion activa por mycobacterium tuberculosis.
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
BR112014017021A2 (pt) inibidores de irak e usos dos mesmos
BR112014014122A2 (pt) tratamento de varizes com base em adesivo
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
PH12014501656A1 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
CL2015001640A1 (es) Heterociclos n-acetilados y de nitrógeno saturados que potencian la actividad de un antibiótico activo contra micobacterias
ECSP14011792A (es) Inhibidores de iap
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
ECSP15003613A (es) Formulación transdérmica que contiene inhibidores de cox
BR112017009237A2 (pt) composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia
BR112018000252A2 (pt) métodos e composições farmacêuticas para intensificar atividades de eliminação de célula nk
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью
BR112018072255A2 (pt) azasteroides para tratamento de tuberculose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ACCESS TO ADVANCED HEALTH INSTITUTE (US)